Abstract: Adult-onset Still's disease can be triggered by pregnancy, requiring a multidisciplinary approach for optimal management and fetal outcomes.
Introduction
Adult-onset Still’s disease (AOSD) is a rare, life-threatening systemic inflammatory disorder. Characterized by high fevers, salmon-colored rashes, and joint pain, it is notoriously difficult to diagnose as its symptoms often mimic common infections or other autoimmune conditions.
When AOSD occurs during pregnancy, the clinical stakes escalate significantly. Physiological changes, specifically rising estrogen levels, may trigger or exacerbate the disease. Untreated AOSD is associated with severe obstetric complications, including intrauterine growth restriction (IUGR), prematurity, and neonatal death. This paper details two successful clinical cases where a multidisciplinary approach managed maternal symptoms and resulted in healthy fetal outcomes despite significant diagnostic hurdles.
Methods and Clinical Presentation
The study presents two primary components: longitudinal case reports of two pregnant patients and a comprehensive literature review.
- Case 1: A patient at 16 weeks gestation newly diagnosed with AOSD.
- Case 2: A patient at 30 weeks gestation newly diagnosed with AOSD.
Diagnosis was established using the Yamaguchi criteria, a high-sensitivity standard requiring the exclusion of infections, malignancies, and other rheumatic conditions. Clinical monitoring involved real-time tracking of biomarkers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and ferritin levels.
Key Insights: The Biological Link
A significant biological insight highlighted is the "Estrogen Trigger." Estrogens can activate macrophages, leading to an overproduction of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1. This suggests that the hormonal surge inherent to pregnancy may be the direct catalyst for AOSD onset or recurrence.
Furthermore, serum ferritin levels served as a critical "red flag"; in Case 1, levels exceeded 2,000 μg/L, aiding diagnosis when standard infection screenings were negative. Pregnancy-associated AOSD tends to follow monocyclic or polycyclic patterns rather than progressing into chronic arthritis, making timely intervention crucial.
Results and Treatment Efficacy
Both patients achieved clinical remission through tailored immunosuppressive regimens.
- Case 1: Responded effectively to a combination of methylprednisolone (mPSL) and cyclosporine A (CsA), leading to a healthy vaginal delivery.
- Case 2: A more refractory case that required a cesarean section at 34 weeks due to fetal growth restriction. Postpartum stabilization was achieved after adding methotrexate to the regimen.
Despite historical data suggesting nearly 50% of AOSD pregnancies involve complications, both cases in this report resulted in healthy infants. The study reinforces that while corticosteroids are the first-line treatment, cyclosporine is a viable and effective second-line disease-modifying antirheumatic drug (DMARD) with a relatively safe profile during pregnancy.
Conclusion and Future Directions
The successful management of these cases underscores the necessity of a collaborative approach involving rheumatologists and obstetricians. However, the study is limited by its small sample size. While biologics like IL-1 or IL-6 inhibitors show promise for refractory cases, large-scale prospective trials are needed to confirm fetal safety. Future work should focus on establishing standardized international diagnostic and treatment protocols specifically for the pregnant population to minimize diagnostic delays and improve maternal and fetal survival rates.
Summary updated